Our present study showed that blocking PLSCR1 activity with a corresponding antibody in CRC cells resulted in downregulation of cyclin D1 and reduced phosphorylation of signaling-related molecules, such Shc, Src, and Erk kinases (Figures 5 and7). Here, SRC is linked to colorectal carcinoma.